Home > Boards > US OTC > Medical - Drugs > Roche Holding Ltd. (RHHBY)

News - Phase III PEMPHIX Study Shows

Public Reply | Private Reply | Keep | Last ReadPost New MsgPrevious | Next
Golden_Cross Member Profile
Member Level 
Followed By 1,725
Posts 46,917
Boards Moderated 65
Alias Born 10/05/05
160x600 placeholder
Genentech: Tecentriq Misses Endpoint in Muscle-Invasive Urothelial Cancer Dow Jones News - 1/24/2020 7:52:00 AM
Illumina, Roche Enter Partnership to Use Genomics for Medical Diagnosis Dow Jones News - 1/13/2020 1:14:00 PM
Bristol-Myers Squibb, Macy's, Grubhub: Stocks That Defined the Week Dow Jones News - 1/10/2020 6:33:00 PM
Sarepta Shares Gain After Licensing Deal With Roche Dow Jones News - 12/23/2019 7:48:00 AM
Drugmakers Turn to Data Mining to Avoid Expensive, Lengthy Drug Trials Dow Jones News - 12/23/2019 5:59:00 AM
Sensyne Health Signs AI Research Pact With Roche Dow Jones News - 12/23/2019 5:31:00 AM
Roche Enters Licensing Agreement With Sarepta Therapeutics for Gene Therapy Dow Jones News - 12/23/2019 2:25:00 AM
Genentech: Tecentriq/Cotellic/Zelboraf Combo Study Meets Primary Endpoint Dow Jones News - 12/13/2019 7:37:00 AM
Genentech: Subcutaneous Perjeta/Herceptin Combo Comparable to IV Dow Jones News - 12/12/2019 11:44:00 AM
Novartis: FDA Accepts Xolair sBLA for Nasal Polyps Dow Jones News - 12/11/2019 6:37:00 AM
Roche Approves Proposals for Board and Executive Committee Dow Jones News - 12/9/2019 2:50:00 AM
Roche Extends Tender Offer for Spark Therapeutics Dow Jones News - 12/9/2019 2:16:00 AM
FDA Approves Marketing of Roche Diagnostics MRSA Diagnostic Test Dow Jones News - 12/5/2019 1:10:00 PM
Genentech: FDA Approves Tecentriq Plus Chemotherapy for Some Non-Small Cell Lung Cancer Dow Jones News - 12/3/2019 7:21:00 PM
Genentech Gets FDA Priority Review for Risdiplam for Spinal Muscular Atrophy Dow Jones News - 11/25/2019 7:36:00 AM
FDA Accepts Avastin Biosimilar BLA From Biogen, Samsung BioLogics Venture Dow Jones News - 11/19/2019 8:45:00 AM
New Hope in the Battle Against Ovarian Cancer NetworkNewsWire - 11/5/2019 8:45:00 AM
Delivering Precision Medicine’s True Potential: Big Data, Artificial Intelligence Identify New Cancer Therapeutics NetworkNewsWire - 10/29/2019 8:45:00 AM
U.K.'s Competition Watchdog Opens Probe into Roche Takeover of Spark Therapeutics Dow Jones News - 10/22/2019 2:46:00 AM
Roche: Phase 3 Study of Tecentriq, Avastin Combination a Success Dow Jones News - 10/21/2019 1:44:00 AM
Roche Says Outlook Is Improving as Revenue Grows Dow Jones News - 10/16/2019 1:48:00 AM
Roche Holding: Results From Tecentriq Study in Bladder Cancer Positive Dow Jones News - 9/30/2019 11:20:00 AM
Genentech Gets FDA Approval for Rituxan in Children With Two Rare Blood Vessel Disorders Dow Jones News - 9/27/2019 2:32:00 PM
Genentech Says Data Positive From Tecentriq Lung Cancer Study Dow Jones News - 9/27/2019 11:20:00 AM
U.K. Regulator to Probe Roche's Acquisition of Spark Therapeutics Dow Jones News - 9/25/2019 2:54:00 AM
Golden_Cross Member Level  Monday, 10/14/19 07:26:16 AM
Re: TopMarketGainers post# 137
Post # of 138 
News - Phase III PEMPHIX Study Shows Genentech’s Rituxan (rituximab) Superior to Mycophenolate Mofetil in Patients With Pemphigus Vulgaris
Press Release | 10/14/2019
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced data from the Phase III PEMPHIX study evaluating the efficacy and safety of Rituxan® (rituximab) compared to mycophenolate mofetil (MMF), in adults with moderate to severe pemphigus vulgaris (PV). The study met the primary endpoint at week 52 and demonstrated that Rituxan is superior to MMF, with 40.3% of patients treated with Rituxan achieving sustained complete remission (CR) without the use of steroids for 16 consecutive weeks or more, compared to 9.5% in the MMF arm (p<0.0001). All secondary endpoints were statistically significant in favor of Rituxan: lower cumulative oral corticosteroid dose (mean difference: 1595 mg; p=0.0005), fewer flares (6 vs. 44, p<0.0001), a greater likelihood of sustained CR (hazard ratio [HR]=4.83; p=0.0003), a lesser likelihood of flare (HR=0.15; p<0.0001) and a greater improvement in the Dermatology Life Quality Index (DLQI) at week 52 (estimated mean change from baseline -8.87 vs. -6.00, p=0.0012) compared to the MMF arm. Adverse events were generally consistent with those seen in previous Rituxan clinical studies in PV and other approved autoimmune indications. Results were presented as a late-breaking oral presentation at the 28th Congress of the European Academy of Dermatology and Venereology in Madrid, Spain on October 12 at 9:00 a.m. – 9:15 a.m. CEST (Presentation D3T01.1C).

“The approval of Rituxan for the treatment of pemphigus vulgaris was the first major advancement in the treatment of this rare, serious disease in more than 60 years,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. “The PEMPHIX study showed that 40% of people in the study could achieve complete remission from painful blistering without the need for corticosteroids for 16 weeks or more and that Rituxan may be a superior treatment option to mycophenolate mofetil.”

The study is ongoing, with patients participating in a 48-week safety follow-up period after treatment completion or discontinuation.

PV is a rare, serious and potentially life-threatening condition characterized by progressive painful blistering of the skin and mucous membranes. MMF is an unapproved, commonly used treatment for PV that is recommended in published treatment guidelines. Rituxan became the first biologic therapy for PV when it was approved by the U.S. Food and Drug Administration (FDA) in June 2018 and the European Commission in March 2019. These approvals were based on data from the Roche-supported Ritux 3 clinical trial. The PEMPHIX study provides additional clinical evidence of the effectiveness of Rituxan for PV.

About the PEMPHIX Study

PEMPHIX is a Phase III, randomized, double-blind, double-dummy, active-comparator, parallel-arm, international, multicenter study (NCT02383589) designed to evaluate the efficacy and safety of Rituxan compared with mycophenolate mofetil (MMF) in patients with moderate to severe active pemphigus vulgaris requiring 60-120 mg/day oral prednisone (or equivalent). Participants were randomly assigned to receive Rituxan plus MMF placebo or Rituxan placebo plus MMF for 52 weeks, in combination with 60 or 80 mg oral prednisone, with the aim of tapering to 0 mg/day by week 24. Rituxan was administered at a dose of 1000 mg via intravenous (IV) infusion on day 1 and 15, with a repeat administration on days 168 and 182. MMF was administered at a dose of 2 grams orally daily (starting at 1 g/day on day 1 and titrated to achieve a goal of 2 g/day by week 2). The primary endpoint at week 52 was the percentage of participants who achieved sustained complete remission without experiencing treatment failure. Sustained complete remission was defined as achieving healing of lesions with no new active lesions (i.e., Pemphigus Disease Area Index activity score of 0) while on 0 mg/day prednisone or equivalent, and maintaining this response for at least 16 consecutive weeks, during the 52-week treatment period. Secondary endpoints were cumulative oral corticosteroid dose, number of disease flares, time to sustained complete remission, time to disease flare and health-related quality of life, as measured by the Dermatology Life Quality Index.

About Pemphigus Vulgaris

Pemphigus vulgaris is an autoimmune, blistering disease affecting the skin and mucous membranes. This rare, potentially life-threatening condition accounts for up to 80% of cases of pemphigus, a group of autoimmune disorders which affect 30,000 to 40,000 people in the United States.

What autoimmune diseases does Rituxan treat?

Adults with Rheumatoid Arthritis (RA): with another prescription medicine called methotrexate, to reduce the signs and symptoms of moderate to severe active RA, after treatment with at least one other medicine called a tumor necrosis factor (TNF) antagonist has been used and did not work well enough.

People with Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA) ages 2 years and above: with glucocorticoids.

Adults with Pemphigus Vulgaris (PV): to treat moderate to severe PV.

Rituxan is not indicated in children less than 2 years of age with GPA or MPA or in children with conditions other than GPA or MPA.

Important Side Effect Information

What is the most important information patients should know about Rituxan?

Rituxan can cause serious side effects that can lead to death, including:

Infusion-Related Reactions: Infusion-related reactions are very common side effects of Rituxan treatment. Serious infusion-related reactions can happen during your infusion or within 24 hours after your infusion of Rituxan. Your healthcare provider should give you medicines before your infusion of Rituxan to decrease your chance of having a severe infusion-related reaction
Severe Skin and Mouth Reactions: Tell your healthcare provider or get medical help right away if you get any of these symptoms at any time during your treatment with Rituxan: painful sores or ulcers on your skin, lips, or in your mouth; blisters; peeling skin; rash; or pustules
Hepatitis B Virus (HBV) Reactivation: If you have had hepatitis B or are a carrier of hepatitis B virus, receiving Rituxan could cause the virus to become an active infection again. Hepatitis B reactivation may cause serious liver problems, including liver failure and death. You should not receive Rituxan if you have active hepatitis B liver disease. Your healthcare provider will monitor you for hepatitis B infection during and for several months after you stop receiving Rituxan
Progressive Multifocal Leukoencephalopathy (PML): PML is a rare, serious brain infection caused by a virus that can happen in people who receive Rituxan. People with weakened immune systems can get PML. PML can result in death or severe disability. There is no known treatment, prevention, or cure for PML
Before receiving Rituxan, patients should tell their healthcare provider if they:

have had a severe reaction to Rituxan or a rituximab product
have a history of other medical conditions including:
Heart problems
Irregular heartbeat
Chest pain
Lung or kidney problems
have had a severe infection, currently have an infection, or have a weakened immune system
have had a recent vaccination or are scheduled to receive vaccinations. You should not get certain vaccines before or during treatment with Rituxan
have any other medical conditions
are pregnant or planning to become pregnant. Talk to your healthcare provider about the risks to your unborn baby if you receive Rituxan during pregnancy. Females who are able to become pregnant should use effective birth control (contraception) during treatment with Rituxan and for 12 months after the last dose of Rituxan. Tell your healthcare provider right away if you become pregnant or think that you are pregnant during treatment with Rituxan
are breastfeeding or plan to breastfeed. It is not known if Rituxan passes into your breast milk. Do not breastfeed during treatment and for at least 6 months after your last dose of Rituxan
are taking any medications, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Especially tell your healthcare provider if you take or have taken:
A tumor necrosis factor (TNF) inhibitor medicine
A disease modifying anti-rheumatic drug (DMARD)
What are the possible side effects of Rituxan?

Rituxan can cause serious side effects, including:

Tumor Lysis Syndrome (TLS): TLS is caused by the fast breakdown of cancer cells. TLS can cause you to have kidney failure and the need for dialysis treatment or an abnormal heart rhythm. TLS can happen within 12-24 hours after an infusion of Rituxan. Tell your healthcare provider right away if you have any of the following signs or symptoms of TLS: nausea, vomiting, diarrhea, or lack of energy
Serious Infections: Serious infections can happen during and after treatment with Rituxan and can lead to death. Rituxan can increase your risk of getting infections and can lower the ability of your immune system to fight infections. People with serious infections should not receive Rituxan
Heart Problems: Rituxan may cause chest pain, irregular heartbeats, and heart attack. Your healthcare provider may monitor your heart during and after treatment with Rituxan if you have symptoms of heart problems or have a history of heart problems. Tell your healthcare provider right away if you have chest pain or irregular heartbeats during treatment with Rituxan
Kidney Problems: especially if you are receiving Rituxan for non–Hodgkin’s lymphoma (NHL). Rituxan can cause severe kidney problems that lead to death. Your healthcare provider should do blood tests to check how well your kidneys are working
Stomach and Serious Bowel Problems That Can Sometimes Lead to Death: Bowel problems, including blockage or tears in the bowel, can happen if you receive Rituxan with chemotherapy medicines. Tell your healthcare provider right away if you have any stomach-area pain during treatment with Rituxan
Your healthcare provider will stop treatment with Rituxan if you have severe, serious, or life-threatening side effects.

What are the most common side effects during treatment with Rituxan?

infusion-related reactions
infections (may include fever, chills)
body aches
tiredness
nausea
Other side effects include:

aching joints during or within hours of receiving an infusion
more frequent upper respiratory tract infections
These are not all of the possible side effects with Rituxan.

Contact a healthcare provider for medical advice about side effects. Report side effects to the FDA at (800) FDA-1088 or http://www.fda.gov/medwatch. Patients may also report side effects to Genentech at (888) 835-2555.

Please see the Rituxan Prescribing Information and Medication Guide including Most Serious Side Effects for additional Important Side Effect Information at http://www.rituxan.com.

Genentech and Biogen collaborate on Rituxan in the United States, and Roche markets MabThera in the rest of the world, except Japan, where Rituxan is co-marketed by Chugai and Zenyaku Kogyo Co. Ltd.

About Genentech

Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.


View source version on businesswire.com: https://www.businesswire.com/news/home/20191013005048/en/

Give Me A Follow If You Want To Consistently Find Winners!
Click Here:
https://investorshub.advfn.com/boards/profilea.aspx?user=61470

Please do your own DD...All my posts are my opinion only!
Public Reply | Private Reply | Keep | Last ReadPost New MsgPrevious | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist